The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1
- PMID: 10418898
- DOI: 10.1016/s0264-410x(99)00062-6
The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1
Abstract
The induction of protective immunity with recombinant vaccines is dependent on the identification of adjuvant or delivery systems that can augment immune responses, especially cellular immune responses, to soluble protein antigen. In this study we demonstrate that an adjuvant formulation comprising QS21, a purified form of saponin and 3D-monophosphoryl lipid A (MPL), a nontoxic derivative of lipopolysaccharide (LPS), enhances cellular and humoral immune responses to a recombinant HIV protein. Analysis of cytokine secretion by antigen-specific T-cells from the spleen demonstrated that QS21 augmented Th1 and Th2 responses, whereas addition of 3D-MPL resulted in preferential induction of type 1 T-cells. Furthermore, analysis of the subclass of the IgG antibody in the serum in mice immunized with gp120 with the combined adjuvant formulation confirmed the selective activation of Th1 cells in vivo. 3D-MPL was found to enhance B7-1 expression and IL-12 production by macrophages, which are known to be involved in the LPS-induced enhancement of Th1 responses. Thus 3D-MPL appears to act as an adjuvant, without the toxicity associated with LPS, by controlled and selective potentiating effects on antigen presentation and T-cell activation.
Similar articles
-
Differential immune responses to HIV-1 envelope protein induced by liposomal adjuvant formulations containing monophosphoryl lipid A with or without QS21.Vaccine. 2015 Oct 13;33(42):5578-5587. doi: 10.1016/j.vaccine.2015.09.001. Epub 2015 Sep 13. Vaccine. 2015. PMID: 26372857
-
Identification of QS-21 as an Inflammasome-activating Molecular Component of Saponin Adjuvants.J Biol Chem. 2016 Jan 15;291(3):1123-36. doi: 10.1074/jbc.M115.683011. Epub 2015 Nov 10. J Biol Chem. 2016. PMID: 26555265 Free PMC article.
-
An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site.Vaccine. 2012 Jan 20;30(5):922-30. doi: 10.1016/j.vaccine.2011.11.089. Epub 2011 Dec 4. Vaccine. 2012. PMID: 22142583 Free PMC article.
-
Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review.Phytomedicine. 2019 Jul;60:152905. doi: 10.1016/j.phymed.2019.152905. Epub 2019 Mar 30. Phytomedicine. 2019. PMID: 31182297 Free PMC article. Review.
-
Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems.Expert Rev Vaccines. 2011 Apr;10(4):471-86. doi: 10.1586/erv.11.29. Expert Rev Vaccines. 2011. PMID: 21506645 Review.
Cited by
-
The Immunogenicity of Capsid-Like Particle Vaccines in Combination with Different Adjuvants Using Different Routes of Administration.Vaccines (Basel). 2021 Feb 6;9(2):131. doi: 10.3390/vaccines9020131. Vaccines (Basel). 2021. PMID: 33562114 Free PMC article.
-
A Comparison of Intramuscular and Subcutaneous Administration of LigA Subunit Vaccine Adjuvanted with Neutral Liposomal Formulation Containing Monophosphoryl Lipid A and QS21.Vaccines (Basel). 2020 Sep 1;8(3):494. doi: 10.3390/vaccines8030494. Vaccines (Basel). 2020. PMID: 32882903 Free PMC article.
-
Toll-Like Receptor Ligand Based Adjuvant, PorB, Increases Antigen Deposition on Germinal Center Follicular Dendritic Cells While Enhancing the Follicular Dendritic Cells Network.Front Immunol. 2020 Jun 19;11:1254. doi: 10.3389/fimmu.2020.01254. eCollection 2020. Front Immunol. 2020. PMID: 32636846 Free PMC article.
-
Strong dose response after immunotherapy with PQ grass using conjunctival provocation testing.World Allergy Organ J. 2019 Oct 25;12(11):100075. doi: 10.1016/j.waojou.2019.100075. eCollection 2019 Nov. World Allergy Organ J. 2019. PMID: 31709029 Free PMC article.
-
Enhanced Immunogenicity and Protective Efficacy of a Campylobacter jejuni Conjugate Vaccine Coadministered with Liposomes Containing Monophosphoryl Lipid A and QS-21.mSphere. 2019 May 1;4(3):e00101-19. doi: 10.1128/mSphere.00101-19. mSphere. 2019. PMID: 31043512 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
